Rapid Nexus Nanotech Wound Solutions is a clinical-stage, medtech company that has developed the WORLD’S FIRST NEUROPATHY REGENERATIVE THERAPEUTIC. We are seeking to raise $2M to get to commercialization. Our novel, peripheral neuropathy, tissue healing product, Hemastyl® , is a formulation that rapidly repairs damaged peripheral nerves of diabetic limbs. We are set to disrupt the $13 billion global neuropathy and diabetic foot ulcer markets that are expected to nearly double by 2032 due to rising rates of diabetes.
Experienced Team: $4.5B in exits.
What is Neuropathy and How Does It Affect a Chronic Wound? Neuropathy is the underlying cause of non-healing wounds, also known as chronic wounds. Peripheral neuropathy describes a condition of nerve damage in limbs of patients, especially those who suffer from diabetes. Neuropathy leads to mild to severe skin and muscle degeneration, many times resulting in necrosis. Degeneration leads to very small to large openings in the damaged tissue which lead to non-healing wounds. These wounds are highly susceptible to infections, amputations, sepsis and even death.
High Unmet Need: Today in the US alone, 20-30 million patients suffer from neuropathy. Pre- Pandemic, 500 U.S. patients with diabetes underwent an amputation DAILY as a result of pathophysiologies such as neuropathy and its damage. Preliminary data of post-pandemic numbers are showing that the daily amputation rate has tripled.
In feasibility studies of over 39 documented patients, Hemastyl® has effectively repaired neuropathic tissue and restored sensation to patients’ limbs. Patients have reported that their numb feet or toes regained feeling after treatment with Hemastyl® . This April, we will begin clinical trial enrollment and use biopsies and nerve counts of tissue samples before and after treatment.
How does it work? Hemastyl® is a highly effective, healing gel formulation which easily penetrates. Cytochrome c-oxidase and building block components rapidly build new tissue. Antimicrobials drive a local infection down rapidly.
What makes us different? Competitor products do not even address healing the broken-down tissue. Their focus is on numbing the pain.
Regulatory: Hemastyl® FDA 510k clearance for wound product is anticipated Q3, 2025. DeNovo approval for neuropathy product is anticipated Q4, 2024 to Q1, 2025.
Why Invest? Diabetes is growing at an alarming rate. The ADA states that 50% of the American population are diabetic or pre-diabetic. It has been estimated that over the next 10 years, healthcare will not be able to keep up with the demand for neuropathy and diabetic wound care.
Financial Projections: We project a gross profit of $29M by Year 3 and $148M by Year 5. We are seeking an acquisition in late 2025.
IP: 14 issued and 12 pending utility patents in the US and globally.
Our Vision is to become the standard of care in neuropathy and diabetic foot wound healing. We are beginning to pioneer a preventive product that can be used to combat degenerating neuropathic tissue, the underlying cause of diabetic foot ulcers.
Ready to Ask For Funding for your company?
Post a Funding Request